Corcept Therapeutics Incorporated

NasdaqCM:CORT Stock Report

Market Cap: US$5.5b

Corcept Therapeutics Management

Management criteria checks 3/4

Corcept Therapeutics' CEO is Joseph Belanoff, appointed in Jan 1999, has a tenure of 25.92 years. total yearly compensation is $9.34M, comprised of 11.6% salary and 88.4% bonuses, including company stock and options. directly owns 2.88% of the company’s shares, worth $158.58M. The average tenure of the management team and the board of directors is 4.1 years and 23.2 years respectively.

Key information

Joseph Belanoff

Chief executive officer

US$9.3m

Total compensation

CEO salary percentage11.6%
CEO tenure25.9yrs
CEO ownership2.9%
Management average tenure4.1yrs
Board average tenure23.2yrs

Recent management updates

Recent updates

Corcept Therapeutics Incorporated (NASDAQ:CORT) Looks Just Right With A 25% Price Jump

Dec 04
Corcept Therapeutics Incorporated (NASDAQ:CORT) Looks Just Right With A 25% Price Jump

Corcept Therapeutics Incorporated (NASDAQ:CORT) Stocks Shoot Up 28% But Its P/E Still Looks Reasonable

Sep 28
Corcept Therapeutics Incorporated (NASDAQ:CORT) Stocks Shoot Up 28% But Its P/E Still Looks Reasonable

If EPS Growth Is Important To You, Corcept Therapeutics (NASDAQ:CORT) Presents An Opportunity

Sep 06
If EPS Growth Is Important To You, Corcept Therapeutics (NASDAQ:CORT) Presents An Opportunity

Investors Still Waiting For A Pull Back In Corcept Therapeutics Incorporated (NASDAQ:CORT)

Aug 01
Investors Still Waiting For A Pull Back In Corcept Therapeutics Incorporated (NASDAQ:CORT)

With Corcept Therapeutics Incorporated (NASDAQ:CORT) It Looks Like You'll Get What You Pay For

Apr 15
With Corcept Therapeutics Incorporated (NASDAQ:CORT) It Looks Like You'll Get What You Pay For

We Like Corcept Therapeutics' (NASDAQ:CORT) Earnings For More Than Just Statutory Profit

Feb 22
We Like Corcept Therapeutics' (NASDAQ:CORT) Earnings For More Than Just Statutory Profit

Corcept Therapeutics: Key Catalysts Ahead

Feb 19

CEO Compensation Analysis

How has Joseph Belanoff's remuneration changed compared to Corcept Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

US$140m

Jun 30 2024n/an/a

US$125m

Mar 31 2024n/an/a

US$117m

Dec 31 2023US$9mUS$1m

US$105m

Sep 30 2023n/an/a

US$91m

Jun 30 2023n/an/a

US$94m

Mar 31 2023n/an/a

US$94m

Dec 31 2022US$7mUS$896k

US$101m

Sep 30 2022n/an/a

US$117m

Jun 30 2022n/an/a

US$113m

Mar 31 2022n/an/a

US$112m

Dec 31 2021US$11mUS$844k

US$113m

Sep 30 2021n/an/a

US$106m

Jun 30 2021n/an/a

US$98m

Mar 31 2021n/an/a

US$99m

Dec 31 2020US$6mUS$770k

US$106m

Sep 30 2020n/an/a

US$109m

Jun 30 2020n/an/a

US$114m

Mar 31 2020n/an/a

US$106m

Dec 31 2019US$5mUS$708k

US$94m

Sep 30 2019n/an/a

US$87m

Jun 30 2019n/an/a

US$78m

Mar 31 2019n/an/a

US$76m

Dec 31 2018US$6mUS$680k

US$75m

Sep 30 2018n/an/a

US$152m

Jun 30 2018n/an/a

US$148m

Mar 31 2018n/an/a

US$142m

Dec 31 2017US$4mUS$647k

US$129m

Compensation vs Market: Joseph's total compensation ($USD9.34M) is about average for companies of similar size in the US market ($USD7.98M).

Compensation vs Earnings: Joseph's compensation has increased by more than 20% in the past year.

CEO

Joseph Belanoff (67 yo)

25.9yrs

Tenure

US$9,337,734

Compensation

Dr. Joseph K. Belanoff, M.D., is a Co-Founder of Corcept Therapeutics Incorporated and has been its Chief Executive Officer since 1999 and President since 2014. Dr. Belanoff has been a Faculty Member and h...

Leadership Team

NamePositionTenureCompensationOwnership
Joseph Belanoff
Co-Founder25.9yrsUS$9.34m2.88%
$ 158.6m
Atabak Mokari
CFO & Treasurer3.8yrsUS$3.72m0.012%
$ 671.3k
Sean Maduck
President of Endocrinology8.7yrsUS$3.91m0.10%
$ 5.5m
William Guyer
Chief Development Officer3.3yrsUS$3.86m0.0052%
$ 288.1k
Gary Robb
Chief Business Officer & Secretary10.9yrsUS$3.96m0.038%
$ 2.1m
Joseph Lyon
Chief Accounting & Technology Officer4.4yrsno data0.0084%
$ 459.6k
Hazel Hunt
Chief Scientific Officer4.4yrsUS$3.11m0.11%
$ 6.2m
Amy Flood
Chief Human Resources & Communications Officer3.4yrsno datano data
Monica Tellado
President of Emerging Markets1.1yrsno datano data
Roberto Vieira
President of Oncologyless than a yearno datano data

4.1yrs

Average Tenure

53.5yo

Average Age

Experienced Management: CORT's management team is considered experienced (4.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Joseph Belanoff
Co-Founder25.9yrsUS$9.34m2.88%
$ 158.6m
George Baker
Independent Director25.9yrsUS$492.53k5.07%
$ 278.6m
David Mahoney
Independent Director20.4yrsUS$509.03k1.25%
$ 69.0m
Charles Nemeroff
Member of Scientific Advisory Boardno datano datano data
James Wilson
Independent Chairman25.9yrsUS$1.26m2.11%
$ 116.2m
Florian Holsboer
Member of Scientific Advisory Boardno datano datano data
Bruce McEwen
Member of Scientific Advisory Boardno datano datano data
Ned Kalin
Member of Scientific Advisory Boardno datano datano data
Edo Kloet
Member of Scientific Advisory Boardno datano datano data
Gregg Alton
Independent Director4.8yrsUS$511.53k0%
$ 0
K. Ranga Krishnan
Member of Scientific Advisory Boardno datano datano data
Kimberly Park
Independent Director5.3yrsUS$488.53k0%
$ 0

23.2yrs

Average Tenure

68.5yo

Average Age

Experienced Board: CORT's board of directors are seasoned and experienced ( 23.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 06:20
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Corcept Therapeutics Incorporated is covered by 23 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
David BuckB. Riley Securities, Inc.
Edward NashCanaccord Genuity